Supernus Pharmaceuticals, Inc. (SUPN) Revenue History
Annual and quarterly revenue from 2008 to present
SUPN Revenue Over Time (2008–2025)
SUPN Revenue Growth History
14 of 17 years with positive growth- FY2008 revenue growth
- N/A
- FY2009 revenue growth
- +326.7%
- FY2010 revenue growth
- -99.7%
- FY2011 revenue growth
- +657.5%
- FY2012 revenue growth
- +84.3%
- FY2013 revenue growth
- +712.1%
- FY2014 revenue growth
- +915.4%
- FY2015 revenue growth
- +18.3%
- FY2016 revenue growth
- +48.9%
- FY2017 revenue growth
- +40.6%
- FY2018 revenue growth
- +35.3%
- FY2019 revenue growth
- -3.9%
- FY2020 revenue growth
- +32.5%
- FY2021 revenue growth
- +11.4%
- FY2022 revenue growth
- +15.1%
- FY2023 revenue growth
- -8.9%
- FY2024 revenue growth
- +8.9%
- FY2025 revenue growth
- +8.6%
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $207.7M | +38.6% |
| Q4 2025 | $211.6M | +21.5% |
| Q3 2025 | $192.1M | +9.3% |
| Q2 2025 | $165.5M | -1.7% |
| Q1 2025 | $149.8M | +4.3% |
| Q4 2024 | $174.2M | +6.0% |
| Q3 2024 | $175.7M | +14.2% |
| Q2 2024 | $168.3M | +24.2% |
Multi-year avg. share of annual revenue by fiscal quarter
Revenue Breakdown (FY 2025)
SUPN's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
SUPN Revenue Analysis (2008–2025)
Current Revenue & Growth
As of June 22, 2026, Supernus Pharmaceuticals, Inc. (SUPN) generated trailing twelve-month (TTM) revenue of $776.8 million, reflecting explosive growth of +38.6% year-over-year. The most recent quarter (Q1 2026) recorded $207.7 million in revenue, down 1.8% sequentially.
Historical Growth Trajectory
SUPN's 5-year compound annual growth rate (CAGR) stands at +6.7%, indicating steady revenue expansion. The 3-year CAGR of +2.5% is below the 5-year average, signalling a growth deceleration in recent years. Supernus Pharmaceuticals, Inc.'s highest annual revenue of $719.0 million was recorded in 2025, an all-time high.
Revenue by Segment
SUPN's revenue is primarily driven by Product (47%), Qelbree (23%), and GOCOVRI (11%). The diversified mix across segments reduces dependence on any single product line, which can support more resilient revenue in downturns.
Peer Comparison
Compared to Healthcare sector peers — including PCRX (+4.6% YoY), ACAD (+9.9% YoY), and INVA (+13.6% YoY) — SUPN has outperformed the peer group in revenue growth. Compare SUPN vs PCRX →
SUPN Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| SUPNCurrent | $777M | +38.6% | +6.7% | -5.1% | |
 PCRX | $726M | +4.6% | +11.1% | 4.6% | |
 ACAD | $1.1B | +9.9% | +19.4% | 9.8% | |
 INVA | $425M | +13.6% | +4.8% | 38.5% | |
 PRGO | $4.3B | -3.6% | +0.8% | 8.1% | |
 LNTH | $1.5B | +0.6% | +35.3% | 20.2% |
SUPN Historical Revenue Data (2008–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $719.0M | +8.6% | $644.4M | 89.6% | $-36,864,000 | -5.1% |
| 2024 | $661.8M | +8.9% | $583.9M | 88.2% | $81.7M | 12.3% |
| 2023 | $607.5M | -8.9% | $523.7M | 86.2% | $-5,269,000 | -0.9% |
| 2022 | $667.2M | +15.1% | $580.0M | 86.9% | $46.1M | 6.9% |
| 2021 | $579.8M | +11.4% | $504.7M | 87.1% | $86.0M | 14.8% |
| 2020 | $520.4M | +32.5% | $467.9M | 89.9% | $173.7M | 33.4% |
| 2019 | $392.8M | -3.9% | $376.1M | 95.8% | $148.6M | 37.8% |
| 2018 | $408.9M | +35.3% | $393.5M | 96.2% | $144.4M | 35.3% |
| 2017 | $302.2M | +40.6% | $287.0M | 95.0% | $99.5M | 32.9% |
| 2016 | $215.0M | +48.9% | $203.0M | 94.4% | $54.2M | 25.2% |
| 2015 | $144.4M | +18.3% | $136.0M | 94.2% | $17.7M | 12.2% |
| 2014 | $122.0M | +915.4% | $116.3M | 95.3% | $24.2M | 19.9% |
| 2013 | $12.0M | +712.1% | $10.9M | 90.8% | $-61,920,000 | -515.2% |
| 2012 | $1.5M | +84.3% | $1.5M | 100.0% | $-42,169,000 | -2849.3% |
| 2011 | $803K | +657.5% | $803K | 100.0% | $-37,752,000 | -4701.4% |
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
18+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
SUPN — Frequently Asked Questions
Quick answers to the most common questions about buying SUPN stock.
Is SUPN's revenue growth accelerating or slowing?
SUPN revenue growth is accelerating. TTM revenue reached $777M, up +38.6% year-over-year — ahead of the 5-year CAGR of +6.7%. This indicates the business is expanding faster than its historical baseline.
What is SUPN's revenue history from 2008 to 2026?
Supernus Pharmaceuticals, Inc. (SUPN) revenue history spans 2008 to 2026. TTM revenue as of 2026 is $777M, growing at +38.6% YoY. The 5-year CAGR is +6.7%. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is SUPN's long-term revenue growth rate (CAGR)?
Supernus Pharmaceuticals, Inc.'s 5-year revenue CAGR of +6.7% reflects the sustained nature of its business expansion. As of 2026, the current YoY growth rate of +38.6% is above this long-term average. CAGR is the most reliable measure of sustained revenue momentum for SUPN.
Why does SUPN's quarterly revenue fluctuate?
SUPN quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Supernus Pharmaceuticals, Inc.'s revenue data from 2008 to 2026 shows full historical quarterly detail on this page.
How is SUPN's revenue distributed by segment?
SUPN reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does SUPN's revenue compare to industry peers?
Supernus Pharmaceuticals, Inc. (SUPN) with TTM revenue of $777M and +38.6% YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.